Valuation: StemRIM

Market Cap 19.43B 120M 105M 96.8M 89.72M 170M 11.39B 173M 1.16B 451M 5.62B 451M 441M P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 12.44B 76.82M 67.23M 61.96M 57.43M 109M 7.29B 111M 743M 289M 3.6B 288M 282M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
47.55%
Yield 2024 *
-
Yield 2025 -
1 day+0.98%
1 week-5.20%
Current month-4.32%
1 month+5.08%
3 months+2.31%
6 months+14.81%
Current year+17.87%
1 week 304
Extreme 304
328
1 month 273
Extreme 273
330
Current year 260
Extreme 260
330
1 year 246
Extreme 246
333
3 years 246
Extreme 246
965
5 years 246
Extreme 246
1,518
10 years 246
Extreme 246
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 2022-09-30
Chief Executive Officer 58 2023-10-24
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 66 2007-01-31
Director/Board Member 58 2019-02-28
Director/Board Member 54 2019-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+0.65%-5.20%+1.31%-64.65% 119M
+4.07%+8.45%+25.67%-2.34% 66.11B
-0.24%-3.13%+49.38%+223.97% 55.3B
+1.21%+42.20%+42.20%+42.20% 42.44B
-0.61%+7.44%-48.93%-54.50% 41.28B
-2.48%+13.91%+166.79%-32.89% 32.46B
-1.32%-4.79%+58.07%-25.22% 30.78B
+2.10%+4.14%+75.49%+90.19% 23.1B
-3.65%+8.93%+1.16%+184.50% 20.06B
-0.04%+3.85%+67.76%+135.89% 17.19B
Average +0.23%+4.03%+43.89%+49.71% 32.88B
Weighted average by Cap. +0.65%+4.84%+43.58%+54.86%

Financials

2024 2025
Net sales - -
Net income -2.02B -12.49M -10.93M -10.07M -9.34M -17.72M -1.19B -18.01M -121M -46.97M -585M -46.89M -45.87M -1.93B -11.91M -10.43M -9.61M -8.91M -16.91M -1.13B -17.18M -115M -44.81M -558M -44.73M -43.76M
Net Debt -8.41B -51.95M -45.46M -41.89M -38.83M -73.71M -4.93B -74.9M -502M -195M -2.43B -195M -191M -6.99B -43.2M -37.8M -34.84M -32.29M -61.3M -4.1B -62.29M -418M -162M -2.02B -162M -159M
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
45
Date Price Change Volume
26-07-07 ¥312.00 +0.65% 27,000
26-07-07 ¥310.00 +0.98% 161,700
26-07-06 ¥307.00 -1.92% 228,200
26-07-03 ¥313.00 +0.97% 209,300
26-07-02 ¥310.00 -2.52% 172,900
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4599 Stock